482 related articles for article (PubMed ID: 15184247)
21. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.
Phillips RK; Wallace MH; Lynch PM; Hawk E; Gordon GB; Saunders BP; Wakabayashi N; Shen Y; Zimmerman S; Godio L; Rodrigues-Bigas M; Su LK; Sherman J; Kelloff G; Levin B; Steinbach G;
Gut; 2002 Jun; 50(6):857-60. PubMed ID: 12010890
[TBL] [Abstract][Full Text] [Related]
22. Increased epithelial cell proliferation in the ileal pouch mucosa of patients with familial adenomatous polyposis.
Friederich P; van Heumen BW; Nagtegaal ID; Berkhout M; van Krieken JH; Peters WH; Nagengast FM
Virchows Arch; 2007 Sep; 451(3):659-67. PubMed ID: 17611772
[TBL] [Abstract][Full Text] [Related]
23. Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel.
Reinacher-Schick A; Seidensticker F; Petrasch S; Reiser M; Philippou S; Theegarten D; Freitag G; Schmiegel W
Endoscopy; 2000 Mar; 32(3):245-54. PubMed ID: 10718391
[TBL] [Abstract][Full Text] [Related]
24. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis.
van Stolk R; Stoner G; Hayton WL; Chan K; DeYoung B; Kresty L; Kemmenoe BH; Elson P; Rybicki L; Church J; Provencher K; McLain D; Hawk E; Fryer B; Kelloff G; Ganapathi R; Budd GT
Clin Cancer Res; 2000 Jan; 6(1):78-89. PubMed ID: 10656435
[TBL] [Abstract][Full Text] [Related]
25. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice.
Hansen-Petrik MB; McEntee MF; Jull B; Shi H; Zemel MB; Whelan J
Cancer Res; 2002 Jan; 62(2):403-8. PubMed ID: 11809688
[TBL] [Abstract][Full Text] [Related]
26. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
Daniels S; Robbins J; West CR; Nemeth MA
Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
[TBL] [Abstract][Full Text] [Related]
27. Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.
van Heumen BW; Roelofs HM; Vink-Börger ME; Dekker E; Mathus-Vliegen EM; Dees J; Koornstra JJ; Langers AM; Nagtegaal ID; Kampman E; Peters WH; Nagengast FM
Orphanet J Rare Dis; 2013 Aug; 8():118. PubMed ID: 23919274
[TBL] [Abstract][Full Text] [Related]
28. Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells.
van Heumen BW; Roelofs HM; Te Morsche RH; Marian B; Nagengast FM; Peters WH
Exp Cell Res; 2012 Apr; 318(7):819-27. PubMed ID: 22366264
[TBL] [Abstract][Full Text] [Related]
29. Familial adenomatous polyposis is associated with a marked decrease in alkaline sphingomyelinase activity: a key factor to the unrestrained cell proliferation?
Hertervig E; Nilsson A; Björk J; Hultkrantz R; Duan RD
Br J Cancer; 1999 Sep; 81(2):232-6. PubMed ID: 10496347
[TBL] [Abstract][Full Text] [Related]
30. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis.
Cruz-Correa M; Shoskes DA; Sanchez P; Zhao R; Hylind LM; Wexner SD; Giardiello FM
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):1035-8. PubMed ID: 16757216
[TBL] [Abstract][Full Text] [Related]
31. Use of NSAIDs for the chemoprevention of colorectal cancer.
Herendeen JM; Lindley C
Ann Pharmacother; 2003 Nov; 37(11):1664-74. PubMed ID: 14565811
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug.
Dougados M; Béhier JM; Jolchine I; Calin A; van der Heijde D; Olivieri I; Zeidler H; Herman H
Arthritis Rheum; 2001 Jan; 44(1):180-5. PubMed ID: 11212158
[TBL] [Abstract][Full Text] [Related]
33. Calcium plus vitamin D alters preneoplastic features of colorectal adenomas and rectal mucosa.
Holt PR; Bresalier RS; Ma CK; Liu KF; Lipkin M; Byrd JC; Yang K
Cancer; 2006 Jan; 106(2):287-96. PubMed ID: 16353199
[TBL] [Abstract][Full Text] [Related]
34. Effects of piroxicam on prostaglandin E2 levels in rectal mucosa of adenomatous polyp patients: a randomized phase IIb trial.
Calaluce R; Earnest DL; Heddens D; Einspahr JG; Roe D; Bogert CL; Marshall JR; Alberts DS
Cancer Epidemiol Biomarkers Prev; 2000 Dec; 9(12):1287-92. PubMed ID: 11142413
[TBL] [Abstract][Full Text] [Related]
35. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
[TBL] [Abstract][Full Text] [Related]
36. Celecoxib as adjunctive therapy for treatment of colorectal cancer.
North GL
Ann Pharmacother; 2001 Dec; 35(12):1638-43. PubMed ID: 11793634
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Solomon SD; McMurray JJ; Pfeffer MA; Wittes J; Fowler R; Finn P; Anderson WF; Zauber A; Hawk E; Bertagnolli M;
N Engl J Med; 2005 Mar; 352(11):1071-80. PubMed ID: 15713944
[TBL] [Abstract][Full Text] [Related]
39. A prospective randomized trial on the role of perioperative celecoxib administration for total knee arthroplasty: improving clinical outcomes.
Reuben SS; Buvenandran A; Katz B; Kroin JS
Anesth Analg; 2008 Apr; 106(4):1258-64, table of contents. PubMed ID: 18349203
[TBL] [Abstract][Full Text] [Related]
40. Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Papadimitrakopoulou VA; William WN; Dannenberg AJ; Lippman SM; Lee JJ; Ondrey FG; Peterson DE; Feng L; Atwell A; El-Naggar AK; Nathan CO; Helman JI; Du B; Yueh B; Boyle JO
Clin Cancer Res; 2008 Apr; 14(7):2095-101. PubMed ID: 18381950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
